崔冬,黄亚华,刘智坚,刘俊君,贾玉琳,姜东炬

• 1:中国人民解放军联勤保障部队第九六七医院心内科
• 2:锦州医科大学中国人民解放军联勤保障部队第九六七医院研究生培养基地

摘要(Abstract)：

目的 评估急性ST段抬高型心肌梗死（STEMI）患者接受经皮冠状动脉介入治疗（PCI）术中采用球囊缓慢撤压方法对无复流（NR）和慢血流（SF）现象的预防作用。方法 选取2017年1月至2020年12月就诊于解放军联勤保障部队第九六七医院（原解放军第二一零医院）心内科，符合STEMI诊断标准并接受PCI的患者242例。根据PCI术中球囊撤压方法不同将患者分为球囊缓慢撤压组（试验组，115例）和常规方法撤压组（对照组，127例），收集两组患者的基本临床资料以及PCI的相关资料，比较两组患者PCI术中NR和SF的发生率及术后即刻抬高ST段回落≥50%的比例。结果 （1）两组患者基本临床资料比较，差异均无统计学意义（均P>0.05）;(2)两组患者PCI相关资料比较，差异均无统计学意义（均P>0.05）;(3)两组患者NR和SF发生率比较：球囊预扩张后，两组恢复心肌梗死溶栓治疗试验（TIMI）血流分级Ⅲ级且心肌呈色分级（MBG）≥Ⅱ级的发生率分别为90.4%和85.8%，差异无统计学意义（P=0.270）；支架释放后，试验组NR和SF的发生率明显低于对照组（3.5%比11.0%,P=0.025），差异有统计学意义；支架内球囊后扩张后，试验组NR和SF的发生率明显低于对照组（1.7%比7.9%,P=0.028），差异有统计学意义；（4）两组术后即刻心电图比较：试验组术后即刻心电图抬高ST段回落≥50%的比例明显高于对照组（97.4%比89.8%,P=0.017），差异有统计学意义。结论 STEMI患者行PCI术中采用球囊缓慢撤压方法与常规方法撤压比较，能够明显降低NR和SF的发生率，缩短ST段回落时间。

关键词(KeyWords)： 急性ST段抬高型心肌梗死;经皮冠状动脉介入治疗;球囊撤压;无复流;慢血流;预防

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 崔冬,黄亚华,刘智坚,刘俊君,贾玉琳,姜东炬

参考文献(References)：

• [1]Ramjane K,Han L,Jin C.The diagnosis and treatment of the no-reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention[J].Exp Clin Cardiol,2008,13(3):121-128.
• [2]Morishima I,Sone T,Okumura K,et al.Angiographic noreflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction[J].J Am Coll Cardiol,2000,36(4):1202-1209.
• [3]张新超,于学忠,朱华栋,等.急性冠脉综合征急诊快速诊治指南(2019)[J].临床急诊杂志,2019,20(4):253-262.
• [4]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
• [5]The TIMI Study Group.The thrombolysis in myocardial infarction(TIMI)trial:phase I findings[J].N Engl J Med,1985,312(14):932-936.
• [6]Aggarwal P,Rekwal L,Sinha SK,et al.Predictors of noreflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].Ann Cardiol Angeiol(Paris),2021,70(3):136-142.
• [7]Reffelmann T,Kloner RA.The “no-reflow” phenomenon:basic science and clinical correlates[J].Heart,2002,87(2):162-168.
• [8]Jaffe R,Charron T,Puley G,et al.Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention[J].Circulation,2008,117(24):3152-3156.
• [9]Keeley EC,Boura JA,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction:a quantitative review of 23 randomised trials[J].Lancet,2003,361(9351):13-20.
• [10]Harrison RW,Aggarwal A,Ou FS,et al.American college of cardiology national cardiovascular data registry,incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction[J].Am J Cardiol,2013,111(2):178-184.
• [11]Nair Rajesh G,Jayaprasad N,Madhavan S,et al.Predictors and prognosis of no-reflow during primary percutaneous coronary intervention[J].Proc(Bayl Univ Med Cent),2018,32(1):30-33.
• [12]Magro M,Nauta ST,Simsek C,et al.Usefulness of the SYNTAX score to predict"no reflow"in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].Am J Cardiol,2012,109(5):601-606.
• [13]Salinas P,Jimenez-Valero S,Moreno R,et al.Update in pharmacological management of coronary no-reflow phenomenon[J].Cardiovasc Hematol Agents Med Chem,2012,10(3):256-264.
• [14]Yip HK,Chen MC,Chang HW,et al.Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction:predictors of slow flow and no-reflow phenomenon[J].Chest,2002,122(4):1322-1332.
• [15]Brosh D,Assali A R,Mager A,et al.Effect of noreflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality[J].Am J Cardiol,2007,99(4):442-445.
• [16]Kumar J,O'Connor CT,Kumar R,et al.Coronary noreflow in the modern era:a review of advances in diagnostic techniques and contemporary management[J].Expert Rev Cardiovasc Ther,2019,17(8):605-623.
• [17]Allencherril J,Jneid H,Atar D,et al.Pathophysiology,diagnosis,and management of the no-reflow phenomenon[J].Cardiovasc Drugs Ther,2019,33(5):589-597.
• [18]Niccoli G,Scalone G,Lerman A,et al.Coronary microvascular obstruction in acute myocardial infarction[J].Eur Heart J,2016,37(13):1024-1033.
• [19]Navarese EP,Frediani L,Kandzari DE,et al.Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI:the RESTORE observational study[J].Catheter Cardiovase Interv,2021,97(4):602-611.
• [20]Case BC,Satler LF.The challenges of coronary no-reflow phenomenon[J].Catheter Cardiovasc Interv,2021,97(4):612-613.
• [21]Movahed MR,Butman SM.The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention[J].Cardiovasc Revasc Med,2008,9(1):56-61.
• [22]梁振洋,刘美丽,韩雅玲,等.冠状动脉内注射比伐卢定预防直接经皮冠状动脉介入治疗术中无复流或慢血流的探索性临床研究[J].中国介入心脏病学杂志,2016,24(11):632-637.
• [23]Jaeschke H.Molecular mechanisms of hepatic ischemiareperfusion injury and preconditioning[J].Am J Physiol Gastrointest Liver Physiol,2003,284(1):15-26.
• [24]Badran HM,Fatah AA,Soltan G.Platelet/lymphocyte ratio for prediction of no-reflow phenomenon in ST-elevation myocardial infarction managed with primary percutaneous coronary intervention[J].J Clin Transl Res,2020,6(1):20-26.